Gilead Sciences revises 2026 guidance to adjusted loss
Updated
Updated · The Wall Street Journal · May 7
Gilead Sciences revises 2026 guidance to adjusted loss
10 articles · Updated · The Wall Street Journal · May 7
The drugmaker now sees an adjusted loss of $1.05 to 65 cents a share, versus prior guidance for $8.45 to $8.85 earnings and FactSet forecasts of $8.55.
It said $11.5 billion in acquired in-process R&D charges and financing costs from Tubulis, Oura Medicines and Arcellx deals drove the downgrade, sending shares down 3% after hours.
Gilead nevertheless raised 2026 product sales guidance to $30 billion-$30.4 billion after first-quarter profit, adjusted earnings and revenue beat estimates, helped by 10% growth in HIV sales to $5 billion.
Can Gilead's blockbuster HIV drugs fund its high-risk, multi-billion dollar foray into the competitive cancer therapy market?
Gilead projects a loss despite record sales. Is this the new, costly price of innovation for major drug companies?